Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$12.23 USD
+0.21 (1.75%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $12.22 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
ATXS 12.23 +0.21(1.75%)
Will ATXS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATXS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATXS
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Is a Surprise Coming for Astria Therapeutics (ATXS) This Earnings Season?
ATXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Suncor (SU) Q3 Earnings Preview: What Investors Need to Know
Will NexTier Merger Boost Patterson-UTI's (PTEN) Q3 Earnings?
Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug
Other News for ATXS
Astria Therapeutics to Present at Upcoming Bradykinin Symposium
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
Evercore ISI Keeps Their Buy Rating on Astria Therapeutics (ATXS)
Astria Therapeutics (ATXS) Gets a Buy from Wedbush
Astria Therapeutics price target raised by $1 at Oppenheimer, here's why